Cart
sales@molnova.com
5-((S)-2-Oxo-4-hydroxypentyl)-2-methoxychromone
CAS No. 1431323-50-0
5-((S)-2-Oxo-4-hydroxypentyl)-2-methoxychromone( ——— )
Catalog No. M38598 CAS No. 1431323-50-0
5-((S)-2′-Oxo-4′-hydroxypentyl)-2-methoxychromone
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name5-((S)-2-Oxo-4-hydroxypentyl)-2-methoxychromone
-
NoteResearch use only, not for human use.
-
Brief Description5-((S)-2′-Oxo-4′-hydroxypentyl)-2-methoxychromone
-
Description5-((S)-2′-Oxo-4′-hydroxypentyl)-2-methoxychromone
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number1431323-50-0
-
Formula Weight———
-
Molecular Formula———
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Sodium Hydrogen Sulf...
Sodium Hydrogen Sulfide (hydrate) is, like nitric oxide, an important gaseous mediator that has significant effects on the immunological, neurological, cardiovascular and pulmonary systems of mammals.
-
FIDAS-5
FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding.?FIDAS-5 has anticancer activities.?FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM.FIDAS-5 induces the expression of cell cycle inhibitor, p21WAF1/CIP1. FIDAS-5 (3 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.FIDAS-5 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells.
-
TRV-120027 acetate (...
TRV-120027 acetate is a β-arrestin-1-biased agonist of the angiotensin II receptor type 1 (AT1 receptor) and engages -arrestins while blocking G-protein signaling.
